No, Bexsero Is Not Confirmed to Protect for Six Years — Here's What the Evidence Actually Shows

The claim is that Bexsero, the meningitis B vaccine given to infants in the UK, provides protection for at least six years. That figure is not backed by clinical trial data or endorsed by any major health authority. The verdict is partially false — not because the vaccine doesn't work, but because how long it works is genuinely unknown, and the evidence we do have points to a shorter window than six years.

The European Medicines Agency, which approved Bexsero, states clearly in its product information that the duration of protection has not been established. That's not a technicality — it means no clinical trial has followed vaccinated children long enough to confirm multi-year protection. The EMA also notes that booster doses may be needed.

Studies published in the journal Vaccine found that the antibody levels triggered by Bexsero in infants drop substantially within 12 to 24 months of vaccination. The UK Health Security Agency echoes this concern, noting that waning antibody levels raise real questions about long-term protection. Neither the NHS nor the Meningitis Research Foundation puts a six-year figure on the vaccine's effectiveness.

To be fair to the strongest version of this claim: antibody levels aren't the whole story. Real-world surveillance may show the vaccine still reduces disease even as antibody counts fall, through immune memory. That data is still being gathered. But "still being studied" is very different from "confirmed for six years."

Misinformation like this tends to stick because it sounds specific and reassuring. A vague "we're not sure how long it lasts" is unsatisfying; "six years" feels solid and trustworthy. Watch out for precise-sounding duration claims about any vaccine — if a major health body hasn't confirmed the number, treat it with caution.